Photobiomodulation on Performance in Female Futsal Athletes (PBMT)

March 30, 2026 updated by: Andreo Fernando Aguiar, Universidade Norte do Paraná

Effects of Photobiomodulation Therapy on Physical Performance in Female Futsal Athletes

The aim of this study is to investigate the effects of photobiomodulation therapy (PBMT) on physical performance in female futsal athletes. It is hypothesized that PBMT is superior to placebo condition in improving the ability to perform repeated sprints and aerobic capacity in high-intensity, intermittent activity (i.e., Bangsbo sprint test and yoyo intermittent recovery level-1, respectively).

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

The aim of this project is to investigate the effects of photobiomodulation therapy (PBMT) on physical performance and muscle recovery in female futsal athletes. A crossover experimental studies will be conducted with 15 female futsal athletes. Participants will receive PBMT or placebo 10 minutes before the Bangsbo sprint test (BST) and Yo-Yo Intermittent Recovery Test (YYIR1) at two time points (M1 and M2), separated by a 2-week washout period. PBMT will be applied according to the randomization order at M1 and M2, so that the participant who receives active PBMT at M1 will receive placebo PBMT at M2, and vice versa. The following variables will be analyzed in the BST: (1) Total Time (TT): the sum of the time of all sprints, and Fatigue Index (FI): the difference between the worst and best times. For the yo-yo test, the total distance covered will be analyzed as an indicator of aerobic performance. In addition, the rating of perceived exertion (RPE) will be recorded immediately after the Bangsbo sprint test and after the yo-yo test.

Study Type

Interventional

Enrollment (Estimated)

15

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Women aged 18-35 years.
  • Futsal athlete for at least 2 years.

Exclusion Criteria:

  • Users of tobacco products
  • Use of nutritional supplements or anabolic steroid hormones for at least 6 months prior to the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo PBMT
Participants will receive the placebo Photobiomodulation
Device: Placebo PBMT
Participants will receive the placebo Photobiomodulation.
Experimental: Active PBMT
Participants will receive the active Photobiomodulation.
Device: Active PBMT
Participants will receive the active Photobiomodulation.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physical performance in the Bangsbo Sprint Test
Time Frame: Baseline (M1) and after 2 weeks (M2)
The ability to perform repeated sprints with changes of direction will be assessed using the Bangsbo sprint test (BST). The test consists of seven sprints of 34.2 meters between the starting cone (A) and the finishing cone (E), interspersed with a 25-second active recovery period. During recovery, participants perform a light jog back to the starting point (cone A). The change of direction (right or left) between cones B and C in the first sprint is determined by each participant's individual preference, and subsequent sprints are performed alternately between the right and left sides. Participants will be verbally encouraged to perform their best in all sprints. The following variables were analyzed: total time (sum of all sprints), and fatigue index (FI) = 100 - (average time/best time) x 100). The BST is considered valid and reliable for analyzing aerobic recovery capacity.
Baseline (M1) and after 2 weeks (M2)
Performance in Yoyo intermittent recovery level 1
Time Frame: Baseline (M1) and after 2 weeks (M2)
Aerobic recovery capacity in high-intensity intermittent running will be assessed using the yo-yo intermittent recovery test level 1 (YYIR1). The protocol consists of 40-meter runs (stages) between cones B and C (20 m out + 20 m back) followed by 10 seconds of active recovery between cones A and B (walking a 5 m path). The initial speed of the test is 10 km/h, with a progressive increase in speed by auditory stimulus (beeps) (the time between "beeps" decreases at each stage, forcing the athlete to run faster). The test is terminated when the participant does not reach the marking line (cone B) within the stipulated time in two attempts (even if not consecutive) or is unable to continue the test due to fatigue/exhaustion (6). Participants are verbally encouraged to perform as well as possible during the test. The total distance covered (in meters) will be used as a variable for aerobic performance. The YYIR1 test is considered valid and reliable for analyzing aerobic recovery capacity.
Baseline (M1) and after 2 weeks (M2)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rating of perceived exertion
Time Frame: Baseline (M1) and after 2 weeks (M2)
The rating fo percevied exertion (RPE) will be recorded immediately after the Bangsbo and YYIR1 tests, using the Borg 6-20 scale. The scale contains 15 points ranging from 6 "no effort" to 20 "maximum effort", and the participant indicate a number on the scale that represent their perceived exertion at that moment. RPE is a simple, valid and reliable instrument for assessing perceived exertion in running tests. All participants will be previously familiarized with the scale through the cognitive anchoring procedure.
Baseline (M1) and after 2 weeks (M2)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Universidade Norte do Paraná

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 15, 2026

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

June 10, 2026

Study Registration Dates

First Submitted

March 30, 2026

First Submitted That Met QC Criteria

March 30, 2026

First Posted (Actual)

April 6, 2026

Study Record Updates

Last Update Posted (Actual)

April 6, 2026

Last Update Submitted That Met QC Criteria

March 30, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Study 1 - PBMT and performance

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Exercise

Clinical Trials on Active PBMT

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Suriname

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe